Regurgitation Is Less Responsive to Acid Suppression Than Heartburn in Patients With Gastroesophageal Reflux Disease

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 6, 2012, Pages 612-619

  Kahrilas, Peter J ^a   Jonsson, Andreas ^b   Denison, Hans ^b   Wernersson, Börje ^b   Hughes, Nesta ^c   Howden, Colin W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c OXFORD PHARMAGENESIS LTD   (United Kingdom)

Author keywords

Drug; Esophagus; Pain; PPI; Stomach

Indexed keywords

ESOMEPRAZOLE; LINAPRAZAN;

ARTICLE; DISEASE SEVERITY; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MEDICAL RECORD REVIEW; MOUTH; NON EROSIVE REFLUX DISEASE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-ULCER AGENTS; ESOMEPRAZOLE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; IMIDAZOLES; LARYNGOPHARYNGEAL REFLUX; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84861336022     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.01.022     Document Type: Article

References (12)

1. Kahrilas P.J., Shaheen N.J., Vaezi M.F., et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008, 135:1392-1413.
2. Kahrilas P.J., Shaheen N.J., Vaezi M.F., et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008, 135:1383-1391.
3. Kahrilas P.J., Dent J., Lauritsen K., et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007, 5:1385-1391.
4. Dent J., Kahrilas P.J., Hatlebakk J., et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008, 103:20-26.
5. Shaw M.J., Talley N.J., Beebe T.J., et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001, 96:52-57.
6. Dent J., Vakil N., Jones R., et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond study. Gut 2010, 59:714-721.
7. Vakil N., van Zanten S.V., Kahrilas P., et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101:1900-1920.
8. Kahrilas P.J., Howden C.W., Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011, 106:1419-1425.
9. Eloubeidi M.A., Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 2000, 95:1881-1887.
10. Eslick G.D., Talley N.J. Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study. J Clin Gastroenterol 2009, 43:111-117.
11. Kahrilas P.J., Hughes N., Howden C.W. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011, 60:1473-1478.
12. Holstein B., Holmberg A., Florentzson M., et al. Pharmacokinetic and pharmacodynamic profiles of AZD0865, a novel, potassium-competitive acid blocker. Gastroenterology 2004, 126. Abstract M1440.